Page 23 - Pharmaceutical Firms

Biocon Q2 results: Net profit declines 10% to Rs 168 crore, revenue up 26%

Biocon's core Ebitda came in at Rs 816 crore, up 34 per cent

Alembic Pharma gets USFDA nod for generic cancer treatment medication

Alembic Pharmaceuticals on Monday said it has received approval from the US health regulator to market Cyclophosphamide capsules, used in the treatment of different kinds of cancers, in the American market. The company has received approval from the US Food and Drug Administration (USFDA) to market its product which is a generic version of Hikma Pharmaceuticals USA Inc product, Alembic Pharmaceuticals said in a statement. Cyclophosphamide capsules is an alkylating drug indicated for the treatment of malignant disease and minimal change nephrotic syndrome in pediatric patients. According to IQVIA, cyclophosphamide capsules, 25 mg and 50 mg, have an estimated market size of USD 8 million in the US for twelve months ending Sep 2022. Shares of the drug firm were trading 1.32 per cent down at Rs 630.35 apiece on the BSE.

Piramal Enterprises posts net loss of Rs 1,536 cr on higher provisions

PEL has moved Rs 5,888 crore worth of wholesale assets from Stage 1 to Stage 2 as the management believed there could be potential stress from these assets

Zydus gets establishment inspection report from USFDA for Moraiya plant

Zydus Lifesciences on Monday said it has received an establishment inspection report from the US health regulator for its formulations manufacturing facility in Moraiya near Ahmedabad. The US Food and Drug Administration (USFDA) inspected the facility from July 26 to August 5, 2022, which concluded with four observations. "The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)," it added. The USFDA issues an establishment inspection report (EIR) to an establishment that is the subject of an FDA or FDA-contracted inspection when the agency decides to close the inspection. Shares of Zydus Lifesciences were trading 2.51 per cent up at Rs 450.85 apiece on the BSE.

Chhattisgarh govt's flagship scheme delivers hefty markdown on medicines

The state government has given priority to the health security of the people, the official said

We thrive on products that have limited competition: Top Sun Pharma execs

In a Q&A, the firm's US business head and its group CFO talk about their plans to scale the specialty products business further, and dwell on the company's strategies post-pandemic

Sun Pharma Q2 PAT rises 10.5% YoY to Rs 2,262 crore on robust sales

Gross sales came in at Rs 10,809.2 crore, growing by 13.1% over Q2 last year

Janaushadhi stores for affordable medicines grew 100-times in 8 yrs: Govt

More than Rs 15,360 crore estimated to have been saved due to central government service

Uncertainty on revenue growth, margin outlook hits Gland Pharma stock

The injectable manufacturing company expects the margin pressure to persist due to cost pressures and negative operating leverage.

Wockhardt likely to sell India business to cut debt, focus on UK: Analysts

Company left with low-margin brands in India after selling profitable ones

Piramal Pharma ends at Rs 192 on debut, valued at Rs 22,882 cr at close

Domestic brokerage Motilal Oswal has set a price target of Rs 210 for the stock

Several states initiate action over contaminated cough syrup controversy

According to the media reports, Karnataka has directed all drugmakers to test samples of glycerine and propylene glycol and submit a report within seven days.

Drug regulator halts production at Maiden Pharma's Sonipat unit

Centre forms panel to analyse causal relation between deaths and cough syrups

Preliminary report suggests lapse in manufacturing process at Maiden Pharma

The firm has been in news for supplying contaminated cough syrups to Gambia, which is linked to the deaths of 66 children due to the presence of contaminants

New Jersey-based Amneal Pharma starts mfg operations for Indian market

The firm already has manufacturing units in four Indian cities, all of which are focused on the export market

Existing pharma marketing practices code is adequate: Centre tells SC

Says Indian Pharmaceutical Alliance's investigation report cleared Dolo-650 maker, Micro Labs, of allegations of bribing doctors with freebies worth Rs 1,000 crore

Pharma industry says taking steps to check misuse of codeine drugs

Sales declining anyway and there is no need to ban because of alleged misuse, say experts

Udaan starts multiple deliveries per day for pharmacies in six cities

Softbank-backed B2B e-commerce firm Udaan has started delivering stocks to pharmacies four times a day across six cities and plans to scale up the service to other places after six to eight months, the company said on Thursday. The 4X4 delivery service' has been rolled out after a pilot programme and receiving extensive feedback from pharmacies in select cities, which required enhanced delivery capabilities. During the pilot phase, the business witnessed a 45 per cent rise in orders in the select cities. "As part of the new service offering, Udaan will provide medicine delivery to pharmacies every 4-hour with 4 delivery slot options in a day to order medicines across six cities - Kolkata, Jaipur, Indore, Ahmedabad, Bengaluru and Pune. Udaan plans to scale the '4X4 delivery service' to more cities and towns in the next 6-8 months," the company said in a statement. Udaan Business head for Pharma Category Sanjay Sharma said the company will leverage for the convenience and faster ...

Pharma supply start-up Saveo Healthcare raises $4.5mn in venture round

Company founded by 4 IIT graduates will use money to expand its presence and for improving technology

Torrent Pharma acquires cosmetic derma player Curatio for Rs 2,000 cr

First major acquisition by Aman Mehta after taking charge at Torrent Pharma in August